All In Biotech

Drug Trial Radar · NCT05251714

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy

Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

May 27, 2022

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Treadwell Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Feb 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.

Conditions

  • Advanced Solid Tumor
  • Breast Cancer

Interventions

  • CFI-402257Drug

    Oral once daily in 28 day cycles

  • FulvestrantDrug

    500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the incidence of adverse events of CFI-402257 as a single agent and at the recommended phase 2 dose (RP2D)Time frame: 48 months
  2. To assess the incidence of adverse events of CFI-402257 in combination with fulvestrant and at the recommended phase 2 dose (RP2D)Time frame: 48 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • START San Antonio

    San Antonio, Texas

  • START - Mountain Region

    West Valley City, Utah

  • Virginia Cancer Specialist

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.